(481 days)
Not Found
No
The description focuses on electrochemical measurement and standard performance testing, with no mention of AI or ML.
No
The device is intended for monitoring blood glucose levels, which aids in managing diabetes, but it does not directly treat or prevent a disease. It provides diagnostic information rather than a therapeutic intervention.
Yes
The "Intended Use" section explicitly states that the system is used "as an aid to monitor the effectiveness of diabetes control," which is a diagnostic purpose to track the progression or management of a medical condition.
No
The device description explicitly states that the system consists of a meter and test strips, which are hardware components.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Explicit Statement: The "Intended Use / Indications for Use" section explicitly states: "The Prodigy Choice Blood Glucose Monitoring System is intended for self-testing outside the body (in vitro diagnostic use)..."
- Nature of the Test: The device measures glucose in a biological sample (blood) outside the body. This is the core definition of an in vitro diagnostic test.
- Purpose: The purpose is to provide quantitative measurement of glucose as an aid to monitor the effectiveness of diabetes control, which is a diagnostic purpose.
N/A
Intended Use / Indications for Use
The Prodigy Choice Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips, forearm, palm, upper-arm, calf or thigh. The Prodigy Choice Blood Glucose Monitoring System is intended to be used by a single person and should not be shared.
The Prodigy Choice Blood Glucose Monitoring System is intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The Prodigy Choice Blood Glucose Monitoring System should not be used for the diagnosis of or screening of diabetes or for neonatal use. Alternative site testing should be done only during steady - state times (when glucose is not changing rapidly).
The Prodigy Choice Test Strips are for use with the Prodigy Choice Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips, forearm, palm, upper-arm, calf or thigh.
Product codes
NBW, CGA
Device Description
The Prodigy Choice Blood Glucose Monitoring System consists of a meter and test strips. The system utilizes an electrochemical method-based meter and dry reagent biosensor (test strips) for blood glucose testing. The size of the current is proportional to the amount of glucose present in the sample, providing a quantitative measurement of glucose in fresh whole blood and control solutions.
The Prodigy Choice Blood Glucose Monitoring System is marketed as a meter only with a carrying case, battery, Owner's Manual, Quick Reference Guide, Logbook, and Warranty Card. The Prodigy Choice Blood Glucose Monitoring System is also marketed as a meter kit with a carrying case, battery, Owner's Manual, Quick Reference Guide, Logbook, and Warranty Card, Prodigy Lancing Device, Prodigy Lancets, Prodigy No Coding Test Strips, and Control Solution. The Prodigy No Coding Test Strips utilize the enzyme glucose oxidase, which is derived from recombinant protein derived from the fungus Aspergillus niger.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
fingertips, forearm, palm, upper-arm, calf or thigh
Indicated Patient Age Range
Not Found
Intended User / Care Setting
People with diabetes at home, for "self-testing".
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Prodigy Choice Blood Glucose Monitoring System was tested to the required standards for blood glucose monitoring systems including:
ISO 15197
NCCLS EP9-A
NCCLS SP5-A
ISO 14971
Prodigy Choices Blood Glucose Monitoring System was also tested for label comprehension and usability with a Human Factor Study.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.1345 Glucose test system.
(a)
Identification. A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.(b)
Classification. Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
0
510(k) Summary 807.92(c)
| SPONSOR | 807.92(a)(1) |
|---|---|
| Company Name: | Prodigy Diabetes LLC |
| Company Address: | 9300 Harris Corners Parkway |
| Suite 450 | |
| Charlotte, NC 28269 | |
| Telephone: | 704-285-6400 |
| Fax: | 704-285-6475 |
| Contact Person: | Rick Admani |
| NOV 2 6 2013 |
Summary Preparation Date: October 24, 2013
| DEVICE NAME | 807.92(a)(2) |
|---|---|
| Trade Name: | Prodigy® Choice Blood Glucose Monitoring System |
| Common/Usual Name: | Blood Glucose Meter |
| Classification Name: | System, Test, Blood Glucose, Over the Counter |
| Regulation Number: | 862.1345 |
| Product Code: | NBW, CGA |
| Device Class: | II |
| Panel: | Clinical Chemistry |
PREDICATE DEVICE
807.92(a)(3)
807.92(a)(4)
| Legally Marketed Equivalent Device | ||
|---|---|---|
| Company | Product | 510(k) # |
| Diagnostic Devices, Inc. | Prodigy Voice BGMS | K073118 |
DEVICE DESCRIPTION
The Prodigy Choice Blood Glucose Monitoring System consists of a meter and test strips. The
system utilizes an electrochemical method-based meter and dry reagent biosensor (test strips) for blood glucose testing. The size of the current is proportional to the amount of glucose present in the sample, providing a quantitative measurement of glucose in fresh whole blood and control solutions.
The Prodigy Choice Blood Glucose Monitoring System is marketed as a meter only with a carrying case, battery, Owner's Manual, Quick Reference Guide, Logbook, and Warranty Card. The Prodigy Choice Blood Glucose Monitoring System is also marketed as a meter kit with a
।
1
carrying case, battery, Owner's Manual, Quick Reference Guide, Logbook, and Warranty Card, Prodigy Lancing Device, Prodigy Lancets, Prodigy No Coding Test Strips, and Control Solution. The Prodigy No Coding Test Strips utilize the enzyme glucose oxidase, which is derived from recombinant protein derived from the fungus Aspergillus niger.
DEVICE INTENDED USE
807.92(a)(5)
The Prodigy Choice Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips, forearm, palm, upper-arm, calf or thigh. The Prodigy Choice Blood Glucose Monitoring System is intended to be used by a single person and should not be shared.
The Prodigy Choice Blood Glucose Monitoring System is intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The Prodigy Choice Blood Glucose Monitoring System should not be used for the diagnosis of or screening of diabetes or for neonatal use. Alternative site testing should be done only during steady - state times (when glucose is not changing rapidly).
The Prodigy Choice Test Strips are for use with the Prodigy Choice Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips, forearm, palm, upper-arm, calf or thigh.
COMPARISON OF TECHNICAL CHARACTERISTICS 807.92(a)(6)
Prodigy Choice Blood Glucose Monitoring System has equivalent technological characteristics and intended use as the Prodigy Voice Blood Glucose Monitoring System (K073118). The Choice Blood Glucose Monitoring System does not have the Voice capability.
PERFORMANCE TESTING
807.92(b)
Prodigy Choice Blood Glucose Monitoring System was tested to the required standards for blood glucose monitoring systems including:
ISO 15197 NCCLS EP9-A NCCLS SP5-A ISO 14971
Prodigy Choices Blood Glucose Monitoring System was also tested for label comprehension and usability with a Human Factor Study.
20
2
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-6609 Silver Spring, MD 20993-0002
November 26, 2013
PRODIGY DIABETES CARE. LLC c/o E.J. SMITH SMITH ASSOCIATES 1468 HARWELL AVENUE CROFTON MD 21114
Re: K122340
Trade/Device Name: Prodigy Choice Blood Glucose Monitoring System Regulation Number: 21 CFR 862.1345 Regulation Name: Glucose test system Regulatory Class: 11 Product Code: NBW. CGA Dated: October 21. 2013 Received: October 21, 2013
Dear Mr. Smith:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments. or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Ilisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you. however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA). it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21. Parts 800 to 898. In addition. FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803): good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable. the electronic product radiation control provisions (Sections 531-542 of the Act): 21 CFR 1000-1050.
3
Page 2- E.J. Smith
If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Carol C. Benson -S for
Courtney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
4
| DEPARTMENT OF HEALTH AND HUMAN SERVICES
| Food and Drug Administration | |
|---|---|
| Indications for Use | |
| Form Approved: OMB No. 0910-0120 | |
| Expiration Date: December 31, 2013 | |
| See PRA Statement on last page. | |
| 510(k) Number (if known) |
510(K) Ki 22340
Device Name
Prodigy Choice Blood Ghucose Monitoring System
Indications for Use (Describe)
The Prodigy Choice Blood Clucose Monitoring System is intended to be used for the quantialive measurement of glucose (sugar) in firsh capillary whole blood samples drawn from the lingertips, forearm, palm, call or thigh. The Prodity Choice Blood Glucose Monitoring System is intended to be used by a single person and should not be shared.
The Prodicy Choice Blood Olucose Monitoring System is include the body (In viro digense use) by people
with diabets al home as an ald to monitor the effectiveness of disbets System should not be used for the diagnosis of or secondal use. Alternative site testing should be done only during steady - state times (when glucose is not changing rapidly).
The Prodigy Choice Test Strips are for use with the Prodigy Choles Meter to quantitutively measure glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips, forearm, palm, upper-arm, calf or thigh.
Type of Use (Select one or both, es epplicable) | Prescription Uso (Parl 21 CFR 801 Subpart D)
[8] Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Canter for Devices and Radiological Health (CORH) (Signature)
Stayce Beck
FORM FDA 3881 (9/13)
Page 1 of 2
FWA-Funding-Request-2024.doc